EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Efficacy and Safety Evaluation of Immune Checkpoint Inhibitors in Combination With Chemotherapy for Extensive Small Cell Lung Cancer: Real‐World Evidence

Yuta Yamanaka iD, Yukiko Okuno iD, Keisuke Kamisako iD, Yuta Okazaki iD, Kentaro Nakanishi iD, Yume Sanada iD, Kiyori Yoshida iD, Tatsuki Ikoma iD, Yuki Takeyasu iD, Utae Katsushima iD, Hiroshige Yoshioka iD, Takayasu Kurata iD

Cancer Medicine · 2024

DOI: 10.1002/cam4.70480 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Yuta Yamanaka und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Oncology, Kansai Medical University Hospital, Osaka, Japan. Hauptthemen laut MEDLINE: Small Cell Lung Carcinoma, Immune Checkpoint Inhibitors, Lung Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Extensive small cell lung cancer (ES‐SCLC) are currently managed using first‐line chemotherapy options, including atezolizumab (Atezo) plus etoposide and carboplatin (CE) or durvalumab (Durva) plus etoposide with either cisplatin (PE) or carboplatin (CE). However, a definitive distinction in therapeutic effects between Atezo and Durva in these regimens remains unestablished.

Methods

We analyzed data from 100 patients diagnosed with ES‐SCLC who received immune checkpoint inhibitors (ICIs) as first‐line chemotherapy. Among them, 70 were administered Atezo + CE, 12 received Durva + PE, and 18 received Durva + CE. We assessed the efficacy of the two ICIs across various factors.

Results

The progression‐free survival (PFS) and overall survival (OS) did not significantly differ between Atezo + CE and Durva + CE/PE as first‐line chemotherapy treatments for SCLC. We observed no significant differences in age, sex, performance status (PS), liver metastasis, bone metastasis, or platinum‐based agent usage between the treatment cohorts. However, a marked improvement in PFS and OS was observed in the solitary patient with brain metastasis treated with Atezo + CE.

Conclusion

The primary distinction between these treatments was observed in the management of patients with brain metastasis. The literature lacks comparative studies on the effects of first‐line ICI treatment on the central nervous system, rendering our findings significant in clinical practice. Despite the retrospective nature of this study and the potential for various biases, we recommend the preferential use of Atezo + CE in patients with brain metastasis to potentially enhance prognosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Small Cell Lung CarcinomaImmune Checkpoint InhibitorsLung NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsCarboplatinEtoposideCisplatinHumansMaleFemaleAgedMiddle AgedRetrospective StudiesAntibodies, Monoclonal, HumanizedProgression-Free SurvivalAdultTreatment OutcomeAntibodies, Monoclonal

Stichwörter der Autor:innen

atezolizumabdurvalumabextensive‐stage small cell lung cancerfirst‐line treatmentimmune checkpoint blockadereal‐world evidence

Substanzen

Immune Checkpoint InhibitorsCarboplatinEtoposideCisplatinAntibodies, Monoclonal, HumanizeddurvalumabatezolizumabAntibodies, Monoclonal

Autor:innen und Institutionen

  • Department of Thoracic Oncology, Kansai Medical University Hospital, Osaka, Japan.

ORCID-Profile: Yuta Yamanaka, Yukiko Okuno, Keisuke Kamisako, Yuta Okazaki, Kentaro Nakanishi, Yume Sanada, Kiyori Yoshida, Tatsuki Ikoma, Yuki Takeyasu, Utae Katsushima, Hiroshige Yoshioka, Takayasu Kurata

Zitieren

APA

Yamanaka, Y., Okuno, Y., Kamisako, K., Okazaki, Y., Nakanishi, K., Sanada, Y., Yoshida, K., Ikoma, T., Takeyasu, Y., Katsushima, U., Yoshioka, H., & Kurata, T. (2024). Efficacy and Safety Evaluation of Immune Checkpoint Inhibitors in Combination With Chemotherapy for Extensive Small Cell Lung Cancer: Real‐World Evidence. Cancer Medicine. https://doi.org/10.1002/cam4.70480

Vancouver

Yamanaka Y, Okuno Y, Kamisako K, Okazaki Y, Nakanishi K, Sanada Y, et al. Efficacy and Safety Evaluation of Immune Checkpoint Inhibitors in Combination With Chemotherapy for Extensive Small Cell Lung Cancer: Real‐World Evidence. Cancer Medicine. 2024. doi:10.1002/cam4.70480

BibTeX
@article{Yamanaka2024,
  author = {Yamanaka, Yuta and Okuno, Yukiko and Kamisako, Keisuke and Okazaki, Yuta and Nakanishi, Kentaro and Sanada, Yume and Yoshida, Kiyori and Ikoma, Tatsuki and Takeyasu, Yuki and Katsushima, Utae and Yoshioka, Hiroshige and Kurata, Takayasu},
  title = {Efficacy and Safety Evaluation of Immune Checkpoint Inhibitors in Combination With Chemotherapy for Extensive Small Cell Lung Cancer: Real‐World Evidence},
  journal = {Cancer Medicine},
  year = {2024},
  doi = {10.1002/cam4.70480}
}
Kostenlos starten →